Glucagon-like Peptide 1 / GLP-1 (7-36)

<strong>Glucagon-like Peptide 1 / GLP-1 (7-36)</strong>_x000D_ <strong>Catalog number:</strong> B2016848_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 3297.7 Dalton (30 aa) monomer_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Glucagon-like peptide 1, GLP-1, Incretin hormone_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Sternkopf M, Nagy M, Baaten CCFMJ, Kuijpers MJE, Tullemans BME, Wirth J, Theelen W, Mastenbroek TG, Lehrke M, Winnerling B, Baerts L, Marx N, De Meester I, Döring Y, Cosemans JMEM, Daiber A, Steven S, Jankowski J, Heemskerk JWM, Noels H. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):e65-e77._x000D_ 2: Barale C, Buracco S, Cavalot F, Frascaroli C, Guerrasio A, Russo I. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation Thromb Haemost. 2017 Jun 2;117(6):1115-1128._x000D_ 3: Eng H, Sharma R, McDonald TS, Landis MS, Stevens BD, Kalgutkar AS. Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs Xenobiotica. 2014 Sep;44(9):842-8._x000D_ 4: Kuc RE, Maguire JJ, Siew K, Patel S, Derksen DR, Margaret Jackson V, O'Shaughnessey KM, Davenport AP. Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta Life Sci. 2014 May 2;102(2):134-8._x000D_ 5: Li N, Lu J, Willars GB. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor PLoS One. 2012;7(10):e47936._x000D_ 6: Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity J Endocrinol. 2004 Mar;180(3):379-88._x000D_ 7: Dong JZ, Shen Y, Zhang J, Tsomaia N, Mierke DF, Taylor JE. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes Diabetes Obes Metab. 2011 Jan;13(1):19-25._x000D_ 8: O'Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice Regul Pept. 2001 Jan 12;96(3):95-104._x000D_ 9: Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice Diabetologia. 2011 Oct;54(10):2649-59._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/29728598">10: Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease Nat Rev Endocrinol. 2018 Jul;14(7):390-403. </a>_x000D_ _x000D_ <strong>Products Related to Glucagon-like Peptide 1 / GLP-1 (7-36) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>